The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses TBIA is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma.
Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.
It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID antibody and antigen testing kits. Certain statements contained in this press release may constitute forward-looking statements.
For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities.
Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U. Securities and Exchange Commission. Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing and to bring improved insights to patients with breast cancer globally. Heat also looks forward. Shares of Biogen Inc. Analysts there cite the need to wait and see how the new rule proposing limited access to Biogen's Alzheimer's disease drug Aduhelm and other drugs in the same class of treatments to clinical trials in order to receive federal reimbursement plays out.
Passion to help medical device companies capitalize on these opportunities drive our advisors. To learn more about how we can support the development, validation, design, and submission of your device with the appropriate regulatory body, please see our full list of services. Twitter LinkedIn. The United States of America has some of the top clinical research organizations in the world.
With its mission to bring new and innovative medicines to patients sooner, it has worked on more than 50 drugs available in the market today. It provides drug development services across all phases of development and multiple therapeutic areas. Working to enhance healthcare by integrating health information technologies and clinical research, IQVIA explores a new path to better health outcomes via Human Data Science.
It integrates the study of human science with breakthroughs in data science and technology to advance our understanding of human health, and help everyone make better, more insightful decisions. Syneos Health integrates all the disciplines involved in bringing new therapies to market, from clinical to commercial, for biopharmaceutical solutions. Parexel International is involved in advancing the success of biopharmaceutical and medical device industries for the development and commercialization of new medical therapies worldwide.
P Founded: When carefully conducted, they are the safest and fastest way to find new treatments and ways to improve health. Volunteers who participate in the study must agree to the rules and terms outlined in the protocol.
Similarly, researchers, doctors, and other health professionals who manage the clinical trials must follow strict rules set by the FDA. These rules make sure that those who agree to participate are treated as safely as possible.
Learn more about the basics of clinical trial participation, read first hand experiences from actual clinical trial volunteers, and see explanations from researchers at the NIH Clinical Research Trials and You Web site. Some people participate in clinical trials because none of the standard approved treatment options have worked, or they are unable to tolerate certain side effects.
Clinical trials provide another option when standard therapy has failed. Others participate in trials because they want to contribute to the advancement of medical knowledge. All clinical trials have guidelines, called eligibility criteria, about who can participate. The criteria are based on such factors as age, sex, type and stage of disease, previous treatment history, and other medical conditions.
This helps to reduce the variation within the study and to ensure that the researchers will be able to answer the questions they plan to study. Therefore, not everyone who applies for a clinical trial will be accepted.
0コメント